Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Below, we share with you three top-ranked, market-neutral funds. Each has earned a Zacks Mutual Fund Rank #1.
British drugmaker GSK said on Wednesday its long-acting injectable HIV therapy showed promise in keeping the viral load suppressed compared to daily oral treatment, especially in individuals facing challenges with pill intake. The interim analysis of a late-stage trial on the therapy known as Cabenuva demonstrated superior efficacy in maintaining viral load suppression compared to daily oral therapy in individuals with a history of adherence challenges to oral antiretroviral treatment, which is used to suppress and mitigate the progression of the disease. The lack of consistent adherence is a common reason why some people living with HIV struggle to keep the virus in check, GSK said.